About the Anticancer Drug Development Session
Anticancer drug development stands at the forefront of cancer research, aiming to revolutionize treatment modalities and improve patient outcomes. Scientists employ various innovative approaches, including targeted therapies, immunotherapy, and precision medicine, to combat cancer's heterogeneous nature. Targeted therapies selectively attack cancer cells while sparing healthy tissues, minimizing side effects. Immunotherapy harnesses the body's immune system to recognize and destroy cancer cells, offering promising results across diverse cancer types. Furthermore, precision medicine tailors treatment strategies based on individual genetic profiles, optimizing efficacy and minimizing resistance. Collaborative efforts between researchers, clinicians, and pharmaceutical companies drive the relentless pursuit of novel anticancer agents, offering hope for enhanced survival rates and improved quality of life for cancer patients worldwide.
Topics Covered in Anticancer Drug Development
Target Identification
High-Throughput Screening
Lead Optimization
Preclinical Tumor Models
Dose-Escalation Studies
Regulatory Approval
Related Scientific Sessions at CIOC 2027
Why Attend the Anticancer Drug Development Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Anticancer Drug Development work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Anticancer Drug Development research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Anticancer Drug Development track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Anticancer Drug Development Conference 2027 — FAQs
What is the Anticancer Drug Development track at CIOC 2027?
The Anticancer Drug Development track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Anticancer Drug Development. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Anticancer Drug Development sessions?
Cancer researchers and clinicians, educators and students with an interest in Anticancer Drug Development are all welcome — whether presenting or attending.
Can I present my research in the Anticancer Drug Development track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Anticancer Drug Development sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Anticancer Drug Development track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.